3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
89
Neoplasms
6
HER2-positive Breast Cancer
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Rectal Neoplasms
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Locally Advanced Breast Cancer
2
Inflammatory Breast Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Solid Cancers
1
Salivary Gland Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Interventions
Carboplatin
5
Trastuzumab
4
Paclitaxel
4
Cyclophosphamide
3
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
pertuzumab
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Vorinostat
1
Thiotepa
1
Taxes
1
Radiotherapy
1
Pharmaceutical Preparations
1
Melphalan
1
Lapatinib
1
Imatinib Mesylate
1
Epirubicin
1
Drugs, Investigational
1
Doxorubicin
1
Docetaxel
1
Denosumab
1
Cryosurgery
1
Cisplatin
1
Chemotherapy, Adjuvant
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Ductal, Breast
×
pertuzumab
×
Clear all
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled